Jinwu Financial News | Lepu Biotech (02157) traded shares at a discounted price and fell in response. As of press release, it reported HK$4.98, down 5.5%, with a turnover of HK$31.21,000.
According to the announcement, on May 17, 2024, the company (as issuer) entered into a placement agreement with the placement agent (CITIC Securities and HSBC). According to this, it is intended to allocate a maximum of 51.17 million H shares to no less than six independent undertakers, accounting for approximately 3.09% and 2.99% of the expanded H shares and the total issued share capital, respectively. The placement price per share was HK$4.58, a 13.09% discount on the closing price of HK$5.27 on the previous trading day.
The total proceeds from the placement will be approximately HK$234 million, and the net amount will be approximately HK$230 million. It is proposed to use about 70% of the net amount for R&D, clinical trials, registration and other work processes of the company's ADC candidate product; about 20% for clinical trials and other work processes of the company's oncolytic virus candidate CG0070; and about 10% to supplement the company's working capital and general corporate use.